Sisram Med Ltd

Hello, welcome to join the Cicero Medical Technology Annual Report in 2023 conference call. All attendees are muted now. Here we go with a disclaimer. This conference call is only open to CineLink's professional institutional investors or invited clients for the exchange of research views only. The content of conference doesn't stand for private investment opinions. Without the prior written permission of Simulink Securities, any institution or individual is strictly prohibited from disclosing the contents and relevant information of the conference in any form, share with others, download, spread, copy, edit, modify, interpret, and so on. We will resolve all the legal rights for those suspected of violating the above. Thank you for your understanding and support. There will be question and answer session after the guest finishes his speech. Now, let's welcome the host of CineLink to speak. Thank you. Good morning and welcome to CISREN Medical Earnings Call for the first half of year 2023. has a job in a pharmaceutical analyst from Sinalink Securities. Please note, this event is being recorded. I would now like to turn the call over to the RR team.

Mary, please go ahead.

Thank you, operator, and everyone for joining us today. Welcome to CISFIRM's earnings call. I would like to remind our listeners that certain information provided in this call may contain forward-looking statements. and changes in business, competitive, technological, regulatory, and other factors could cause actual results to differ materially from the forward-looking statements made today. Our historical results are not necessarily indicative of future performance. As such, we can give no assurance as to the accuracy of our forward-looking statements and assume no obligation to update them except as required by law. This safe harbor statement applies to the call. If you have not received the copy of the release, please visit the investor relations section of the company's website. Now, I'd like to introduce the speakers on the call. With us on the line today are Mr. Liu Yi, CISRAM's chairman, Mr. Lior Dayan, CISRAM's chief executive officer, Mr. Doron Yanai, Alma's CFO, and Ms. Shanli Fang, CISRAM's Secretary of the Board. Management will start with an overview of the business developments in the first half of 2023. Following the prepared remarks, we will open the call for the question and answer session. With that, I'd like to turn the call over to Mr. Lior Dayan, CISRAM's Chief Executive Officer. Please go ahead.